Aminoglycosides: Perspectives for Clinical Use in Russia

Clinical Microbiology and Antimicrobial Chemotherapy. 2008; 10(3):260-269

​ Reshedko G.K.
aminoglycoside nosocomial infections epidemiology antimicrobial resistance
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2008; 10(3):260-269

Abstract

The susceptibility to aminoglycoside antimicrobials of Gram-negative nosocomial pathogens in Russia and mechanisms of aminoglycoside resistance has been studied. The production of aminoglycoside-modifying enzymes remains to be the major mechanism of aminoglycoside resistance in Russia. High resistance rates to gentamicin and tobramycin were determined by production of enzymes ANT(2″) and AAC(3)-V. Resistance to amikacin was associated with APH(3′)-VI; this enzyme was noted to be highly prevalent in Acinetobacter spp. and Enterobacteriaceae. Interesting that netilmycin remains active against number of gentamicin- and amikacin-resistant isolates of Acinetobacter spp. and Enterobacteriaceae.

  • 1. Страчунский Л.С. Проблемы и перспективы антибактериальной терапии. Российские медицинские вести1998; (1):23-27.
  • 2. Begg E.J., Barclay M.L., Kirkpatrick C.J.M. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 1999; 47:23-30.
  • 3. Cookson B. Clinical significance of emergence of bacterial antimicrobial resistance in the hospital environment. J Appl Microbiol 2005; 99:989-96.
  • 4. Rello J., Rue M., Jubert P., et al. Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent. Crit Care Med 1997; 25:1862-7.
  • 5. Jones M.E., Karlowsky J.A., Draghi D.C. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003; 22:406-19.
  • 6. Fish D.N., Ohlinger M.J. Antimicrobial resistance: factors and outcomes. Crit Care Clin 2006; 22:291-311.
  • 7. Kollef M.H., Micek S.T. Strategies to prevent antimicrobial resistance in the intensive care unit. Crit Care Med. 2005;33:1845-53.
  • 8. Решедько Г.К., Рябкова Е.Л., Кречикова О.И., Сухорукова М.В., Шевченко О.В., Эйдельштейн М.В. Резистентность к антибиотикам грамотрицательных возбудителей нозокомиальных инфекций в ОРИТ многопрофильных стационаров России. Клин микробиол антимикроб химиотер 2008; 10:96-112.
  • 9. Hanberger H., Erlandsson M., Burman L.G., et. al. High antibiotic susceptibility among bacterial pathogens in Swedish ICUs. Report from a nation-wide surveillance program using TA90 as a novel index of susceptibility. Scand J Infect Dis 2004; 36:24-30.
  • 10. Mittermayer H., Rotter M., Breitfellner G., et. al Resistance of gram-negative bacilli and staphylococci from blood cultures to aminoglycoside antibiotics. Comparison of 3 in vitro investigations from Austria 1982-1988. Zentralbl Bakteriol 1990; 272:448-57.
  • 11. Harrell L.R., Evans L.B. Anaerobic resistance of clinical isolates of Staphylococcus aureus to aminoglycosides. Antimicrob Agents Chemother 1978; 14:927-9.
  • 12. Gospodarek E. Susceptibility to antibiotics and biochemical activity of strains Acinetobacter sp. isolated from various sources. Med Dosw Microbiol 1993; 45:331-7.
  • 13. Reller L.B., Schoenknecht F.D., Kenny M.A., et al. Antibiotic susceptibility testing of Pseudomonas aeruginosa: selection of a control strain and criteria for magnesium and calcium content in media. Antimicrob Agents Chemother 1987; 31:1514-8.
  • 14. Решедько Г.К. Особенности резистентности грамотрицательных возбудителей нозокомиальных инфекций к аминогликозидам в России. Антибиотики и химиотерапия 2004; 49:6-18.
  • 15. Miller G.H. and aminoglycoside resistance study groups. Increasing complexity of aminoglycoside resistance mechanisms in gram-negative bacteria. APUA Newsletter 1994; 12.
  • 16. Вакуленко С.Б. Бактериальные ферменты, инактивирующие аминогликозидные антибиотики и кодирующие их гены. Антибиотики 1992; 4:49-54.
  • 17. Rice L.B., Bonomo R.A. Genetic and biochemical mechanisms of bacterial resistance to antimicrobial agents. In: Lorian V., editor. Antibiotics in laboratory medicine. New York: Williams & Wilkins; 1996. p. 453-501.
  • 18. Miller G.H. Aminoglycoside Resistance Surveys Team. USA: Schering-Plough Research Institute. 1992.
  • 19. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: 14th informational supplement. NCCLS document M100-S14. 2004. National Committee for Clinical Laboratory Standards, Wayne, PA.
  • 20. Miller G. H., Sabatelli F. J., Naples L. The utilization of aminoglycoside resistance phenotypes for the determination of aminoglycoside resistance mechanisms. ScheringPlough Research Institute 1995.
  • 21. Сидоренко С.В. Фармакодинамика антибиотиков. Кли­ническая фармакология и терапия 2002; 11(2):12- 15.
  • 22. Nemec A., Maixnerová M. Aminoglycoside resistance of Acinetobacter baumannii hospital strains in the Czech Republic. Klin Mikrobiol Infekc Lek 2004; 10:223-8.
  • 23. McGowan J. E. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Antimicrob Resistance 1983; 5:1033-48.
  • 24. Montie T., Patamasucon P. Aminoglycosides: the complex problem of antibiotic mechanisms and clinical applications. Eur J Clin Microbiol Infect Dis 1995; 14:85-7.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared